Alpex Pharma SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alpex Pharma SA
Patent board has instituted 19 other inter partes review proceedings sought by the hedge fund manager and declined to institute 14.
Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Drug Delivery
- Controlled Release
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.